RxDoctor Payments Data

John Rocchi, MD

Internal Medicine · Butler, PANPI 1306837091

Payments from drug & device makers

$3,561in general payments, 2019–2025

Across 224 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$624
  • Pfizer$385
  • GSK$352
  • AbbVie$305
  • Amgen$237
  • Astellas Pharma US Inc$190
  • plus $1K from 34 others

What the payments were for

  • Food & beverage$3,44497%
  • Education$1183%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,561 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$139,770
Medicare patients
268
Services billed
1,491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban886$295,577
JardianceEmpagliflozin411$212,499
TradjentaLinagliptin513$160,304
TrulicityDulaglutide99$128,239
OzempicSemaglutide102$110,481
Trelegy ElliptaFluticasone/Umeclidin/Vilanter107$105,840
XareltoRivaroxaban242$99,510
IngrezzaValbenazine Tosylate24$97,873
MyrbetriqMirabegron250$76,102
EntrestoSacubitril/Valsartan104$36,700
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr55$33,770
JanuviaSitagliptin Phosphate86$32,005
MounjaroTirzepatide23$31,440
Breo ElliptaFluticasone/Vilanterol50$28,763
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc268$27,331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$91$390,114945 claims
PfizerEliquis$385$295,577886 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arexvy$352$185,870270 claims
Lilly USA, LLCTrulicity, Mounjaro$113$159,679122 claims
Novo NordiskOzempic, Rybelsus$624$127,232118 claims
Johnson & JohnsonXarelto$105$99,510242 claims
Neurocrine Biosciences, Inc.Ingrezza$27$97,87324 claims
Astellas Pharma US IncMyrbetriq$190$76,102250 claims
MerckJanuvia, Lagevrio (Eua)$139$41,32997 claims
NovartisEntresto$66$36,700104 claims
AstraZenecaFarxiga, Breztri Aerosphere$85$31,629119 claims
AbbVieLinzess$305$14,49222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Butler

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →